Recombinant Human DNMT3B Protein, His-tagged

• Cat.No.: DNMT3B-895H
• Product Overview: Recombinant Human DNMT3B Protein (Ser145-Pro355) with His tag was expressed in 293F.

Specification

• Description: CpG methylation is an epigenetic modification that is important for embryonic development, imprinting, and X-chromosome inactivation. Studies in mice have demonstrated that DNA methylation is required for mammalian development. This gene encodes a DNA methyltransferase which is thought to function in de novo methylation, rather than maintenance methylation. The protein localizes primarily to the nucleus and its expression is developmentally regulated. Mutations in this gene cause the immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome. Eight alternatively spliced transcript variants have been described. The full length sequences of variants 4 and 5 have not been determined.
• Source: HEK293F
• Species: Human
• Tag: His
• Form: Freeze-dried powder
• Molecular Mass: Predicted Molecular Mass: 24.7 kDa; Accurate Molecular Mass: 30/33 kDa
• Protein length: Ser145-Pro355
• Purity: > 90%
• Applications: Positive Control; Immunogen; SDS-PAGE; WB.
• Stability: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37 centigrade for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
• Storage: Avoid repeated freeze/thaw cycles. Store at 2-8 centigrade for one month. Aliquot and store at -80 centigrade for 12 months.
• Storage Buffer: 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
• Reconstitution: Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Gene Information

• Gene Name: DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta [ Homo sapiens (human) ]
• Official Symbol: DNMT3B
• Synonyms: DNMT3B; DNA (cytosine-5-)-methyltransferase 3 beta; DNA (cytosine-5)-methyltransferase 3B; DNA MTase HsaIIIB; DNA methyltransferase HsaIIIB; ICF; ICF1; M.HsaIIIB
• Gene ID: 1789
• mRNA Refseq: NM_001207055
• Protein Refseq: NP_001193984
• MIM: 602900
• UniProt ID: Q9UBC3

Reviews

11/09/2020

The DNMT3B protein is of exceptional quality and has proven to be an ideal choice to meet my experimental requirements.

09/10/2020

With its consistent and outstanding results, the DNMT3B protein is an indispensable tool that I highly recommend for researchers in need of reliable and precise protein analysis.

04/23/2019

Its purity and reliability have consistently resulted in successful outcomes in my research projects, providing me with accurate and reproducible data.

Q&As

What are the potential side effects of targeting DNMT3B for therapeutic purposes?

Targeting DNMT3B for therapeutic purposes may lead to off-target effects and unintended changes in DNA methylation, potentially causing adverse effects on normal cellular function and gene expression.

Are there any genetic disorders associated with mutations in the DNMT3B gene?

Yes, mutations in the DNMT3B gene are linked to a rare genetic disorder called ICF (Immunodeficiency, Centromeric instability, Facial anomalies) syndrome, characterized by immune system deficiencies, facial abnormalities, and unstable centromeric regions in chromosomes.

Can DNMT3B protein be used as a potential biomarker for cancer diagnosis or prognosis?

Research has shown that alterations in DNMT3B expression or activity can be associated with various types of cancer, making it a potential biomarker for cancer diagnosis, prognosis, and treatment response.

How does DNMT3B protein contribute to epigenetic regulation in cells?

DNMT3B plays a crucial role in establishing de novo DNA methylation patterns during embryonic development and cell differentiation, contributing to the epigenetic regulation of gene expression.

What are the therapeutic implications of targeting DNMT3B in cancer treatment?

Inhibition of DNMT3B activity through targeted therapy or epigenetic modifying agents has been explored as a potential treatment strategy to reverse abnormal DNA methylation patterns and restore normal gene expression in cancer cells.